Results 11 to 20 of about 11,074 (164)

Alectinib combined with 5-aminolevulinic acid-based photodynamic therapy promotes apoptosis in endometrial cancer cells by targeting ferrochelatase [PDF]

Frontiers in Oncology
BackgroundHysterectomy is the standard treatment for early-stage endometrial cancer, but this type of surgery is associated with corresponding surgical trauma.
Pengfei Wang, Xian Zhang, Haijing Li, Lujiadai Xue, Yajuan Deng, Hu Li, Kunyong Xie, Xiaoyu Wang, Yuanhong Chen   +8 more
doaj   +2 more sources

High incidence and reversible bradycardia events following alectinib initiation

Thoracic Cancer, 2023
Background With the widespread use of alectinib in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small‐cell lung cancer (NSCLC), its cardiotoxicity has gradually emerged, including new‐onset sinus bradycardia (SB).
Peng Chen, Fuyi Zhu, Ran Zuo
exaly   +2 more sources

Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease

BMC Pulmonary Medicine, 2017
Background Alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, is a key drug for ALK rearranged lung adenocarcinoma. Interstitial lung disease (ILD) is an important adverse effect of alectinib, which generally requires termination ...
Tatsuya Nitawaki, Yoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado   +3 more
doaj   +2 more sources

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung

Surgical Case Reports, 2018
Background Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer ...
Naoko Imanishi, Kazue Yoneda, Akihiro Taira, Yoshinobu Ichiki, Naoko Sato, Masanori Hisaoka, Fumihiro Tanaka   +6 more
doaj   +2 more sources

Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy [PDF]

Frontiers in Pharmacology, 2023
Alectinib has been approved as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung carcinoma. Oncologists are also exploring the possibility of applying alectinib in the perioperative period.
Peijun Cao, Qingchun Zhao, Yongwen Li, Ruifeng Shi, Guangsheng Zhu, Zihe Zhang, Hongbing Zhang, Minghui Liu, Sen Wei, Hongyu Liu, Jun Chen, Jun Chen   +11 more
doaj   +2 more sources

Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin [PDF]

BMC Cancer, 2021
Background Photodynamic therapy with a photosensitizer such as protoporphyrin-IX, a light sensitive metabolite of heme synthesis, is a highly selective treatment for various carcinomas.
Bernhard Gillissen, Antje Richter, Frank Essmann, Wolfgang Kemmner   +3 more
doaj   +2 more sources

Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements

Therapeutic Advances in Medical Oncology
Background and objectives: This study aimed to compare the efficacy of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) alectinib and brigatinib in the treatment of advanced non-small-cell lung cancer (NSCLC) with ...
Kyuhwan Kim, Kyu Yean Kim, Hye Seon Kang, Ah Young Shin, Sung Kyoung Kim, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim, Jeong Uk Lim, Chang Dong Yeo   +9 more
doaj   +2 more sources

First‐Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK‐Positive Non‐Small Cell Lung Cancer with Brain Metastases: A Real‐World Multicenter Study from Vietnam [PDF]

Thoracic Cancer
Background This study compared the efficacy of first‐line alectinib versus ceritinib and evaluated the role of upfront brain radiotherapy (RT) in patients with ALK‐positive non‐small cell lung cancer (NSCLC) and brain metastases (BM).
Hoang Gia Nguyen, Xuan Hau Nguyen, Phuong Nguyen, Thu Huong Nguyen, Quang Bui Vinh   +4 more
doaj   +2 more sources

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report [PDF]

Frontiers in Pharmacology
Anaplastic lymphoma kinase (ALK) inhibitor alectinib has demonstrated significant potential in treating non-small cell lung cancer (NSCLC); however, its adverse effects remain a notable challenge for healthcare professionals.
Yun Li, Ping Yu, Ran Wang
doaj   +2 more sources

A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib

Case Reports in Oncology
Introduction: We would like to share the case of a 55-year-old male patient with ALK-positive lung cancer with a corpuscular hemolytic anemia following alectinib therapy.
X. Tonnar, Cornelius F. Waller
doaj   +2 more sources